GlassScriptPhysician profile
Honey Hull
NPI 1083150304
$1,206.07
in general payments reported to CMS, 2019-2025
15 companies · $35.69 in 2025
The $35.69 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $270 · 2023: $197 · 2024: $246 · 2025: $35.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $275.58 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $239.18 | 2021-2023 | Belbuca, Xtampza |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Eisai INC. | $121.40 | 2024 | |
| Abbvie INC. | $100.31 | 2021-2023 | |
| Grifols USA, LLC | $100.00 | 2022 | |
| Nevro Corp. | $55.55 | 2023 | Senza |
| Grt US Holding, INC. | $45.00 | 2022 | |
| Dexcom, INC. | $35.69 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $28.46 | 2022 | |
| Pfizer INC. | $25.30 | 2021 | |
| Abbott Laboratories | $19.92 | 2023 | Proclaim |
| Bioventus LLC | $12.19 | 2021 | |
| Biodelivery Sciences International, INC. | $11.38 | 2021 | |
| Redhill Biopharma INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Honey Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.